Anebulo Pharmaceuticals’ (ANEB) Speculative Buy Rating Reiterated at Benchmark

Anebulo Pharmaceuticals (NASDAQ:ANEB)‘s stock had its “speculative buy” rating reissued by equities researchers at Benchmark in a research report issued on Tuesday,Benzinga reports. They currently have a $8.00 price objective on the stock. Benchmark’s price objective would suggest a potential upside of 426.32% from the company’s previous close.

Anebulo Pharmaceuticals Stock Performance

Shares of Anebulo Pharmaceuticals stock opened at $1.52 on Tuesday. The company has a market capitalization of $39.42 million, a PE ratio of -5.07 and a beta of -1.00. The company has a 50-day simple moving average of $1.89 and a two-hundred day simple moving average of $2.10. Anebulo Pharmaceuticals has a one year low of $1.46 and a one year high of $3.30.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last posted its quarterly earnings data on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.08. On average, equities analysts predict that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.